One Strip Per Day: Why MIHIYO Doesn't Dose On Demand

▶ Watch the video

By Jack Zheng, MS Pharmacy — Founder of MIHIYO Labs

Summary

MIHIYO Labs dispenses one oral dissolving strip (ODS) per day per product. The design rests on three distinct considerations: dosing-frequency adherence data, a formulation-level film-capacity limit, and a delivery-level oral residence-time limit — only the first speaks directly to frequency itself. A systematic review of electronically monitored medication use found once-daily regimens reach roughly 79 percent patient compliance, versus about 65 percent for three-times-daily dosing, in prescription-medication data. Separately, one film-formulation study found drug loads above 30 percent of dry film mass reduced flexibility and tear resistance. Saliva also clears continuously, limiting how long active stays available before the rest is swallowed. MIHIYO engineers one calibrated dose around these constraints.

Why does MIHIYO dose one strip a day instead of letting people take more?

Customers ask this often enough that it deserves a direct answer: every MIHIYO strip — Energy-Focus, Sleep-Support, Mood-Boost — is formulated as a single daily dose, not a take-as-needed format. That is a deliberate design choice, not a regulatory default. I hold every formulation to two metrics: bioavailability and absorption speed, meaning how much of the active reaches circulation and how fast it gets there — that is the design intent behind every batch, not a measured result published for any MIHIYO product specifically. A one-per-day model is the version of that discipline a customer can follow more simply and consistently, without having to decide when to redose. The reasoning behind it draws on three distinct considerations: how much active a thin polymer film can physically carry (a formulation-level constraint on the dosage form itself, not a frequency argument by itself), how oral residence time and salivary clearance bound the absorption window a single dose gets (a delivery-level constraint, also not a frequency argument on its own), and what the compliance literature says happens once you ask someone to track more than one dose a day — which is the one consideration that actually speaks to dosing frequency directly.

What limits how much active a strip can carry, and how does the mouth's own turnover affect a second dose?

An oral dissolving strip is a thin polymer film that has to hold together, survive packaging, and dissolve against oral tissue for a sustained window of contact rather than clearing in a few seconds like a swallowed tablet — the design target I hold MIHIYO's own films to is roughly 30 to 60 seconds of mucosal contact. That mechanical requirement is not free: it limits how much active ingredient the film can carry. In one formulation study of loratadine-loaded orodispersible films built on a hypromellose matrix, researchers found that drug loads above roughly 30 percent of dry film mass began to reduce film flexibility and tear resistance, even though loads up to that point — about 5 mg per 1.5 cm² in that study — still met pharmacopeial standards for content uniformity.¹ That trade-off is plausibly not unique to loratadine films, since thinner films generally have less matrix to carry a suspended or dissolved active, but the exact threshold is study- and formulation-specific: it depends on the polymer system, the active's own solubility and particle size, plasticizer choice, and target film thickness, and I am not claiming this 30 percent figure as a universal ceiling across all orodispersible films.

The tissue a strip dissolves against is the second constraint, though a narrower one than it might first appear. The mucosa under the tongue and inside the cheek offers a route for systemic absorption that can bypass part of the hepatic first-pass metabolism that limits swallowed forms, and permeability and epithelial thickness both vary by site within the mouth.² That tissue is also bathed in saliva that never stops moving: unstimulated salivary flow in healthy adults runs at a median of roughly 0.48 mL per minute, continuously clearing whatever is dissolved in the mouth toward the gut.³ What that clearance actually limits is oral residence time, not the tissue's total absorptive capacity: salivary flow continuously dilutes dissolved content and promotes its clearance toward the gastrointestinal tract, so only the fraction that crosses the mucosa before clearance is absorbed transmucosally, while the portion that is swallowed follows an ordinary gastrointestinal route and does not receive the same first-pass bypass.²³ That residence-time limit is the honest basis for engineering one well-timed dose — it is not evidence that the mucosa is somehow already "occupied" by an earlier strip and unable to absorb a second one an hour or more later; no source cited here demonstrates transporter saturation or a lasting local barrier effect from a prior dose, and for a passively diffusing molecule a second dose could in principle still add to total systemic exposure.

What the compliance and pharmacokinetic evidence says about dosing frequency

The strongest argument for one dose a day is not pharmacological at all — it is behavioral, and it draws on a well-established pattern in medication-adherence research. A systematic review of studies that used electronic monitoring to track real-world medication-taking found a downward trend in compliance as dosing frequency increased: mean dose-taking compliance was 79 percent with once-daily regimens, 69 percent with twice-daily regimens, and 65 percent with three-times-daily regimens.⁴ Medication studies consistently suggest that simpler dosing schedules tend to be associated with better adherence — but that evidence describes prescription medication use, measured in people managing conditions with real health stakes, and it cannot predict how MIHIYO customers actually take a supplement strip.

Source: Claxton, Cramer, and Pierce, 2001.⁴

The pharmacokinetics of MIHIYO's own actives add formulation-specific reasons to keep dosing simple, each in a different way. Caffeine has a well-characterized elimination half-life of roughly 4 to 5 hours in healthy adults, so a substantial fraction of a morning dose may still be circulating several hours later.⁵ A second caffeine strip taken mid-afternoon adds to caffeine that remains in circulation from the morning dose, increasing total exposure and potentially extending stimulant effects later into the day — a straightforward additive effect, not a mysterious one. Melatonin is a different case: in vitro work on cloned human melatonin receptors found that receptor sensitivity is exposure-dependent — short-term exposure to melatonin differentially altered the functional responsiveness of the two human receptor subtypes, hMT1 and hMT2, in a concentration-related way.⁶ That is a cell-based pharmacology finding, not a clinical claim about what happens in a person who takes an extra strip. I'm including it as mechanistic context worth being aware of, not as proof that a second dose blunts melatonin's effect in practice. 5-HTP evidence adds a related, narrower point: a placebo-controlled challenge study in twelve healthy male volunteers, which tested placebo, 100 mg, 200 mg, and a carbidopa-paired 100 mg arm, found that systemic 5-HTP exposure varied substantially across regimens, with nausea reported in the carbidopa-enhanced regimen.⁷ That study measured a serotonergic challenge response, not mood outcomes, and it does not establish 100 to 200 mg as a clinically effective dose for anything — what it does show is that systemic 5-HTP exposure can change substantially with regimen, while tolerability can also be affected under some dosing conditions.

What this means for each MIHIYO strip

Energy-Focus is built around a single morning-timed caffeine dose because caffeine's multi-hour elimination half-life means a second same-day strip would add to caffeine still circulating from the first, not start from zero — the strip is designed to be felt once and to fade over its expected multi-hour time course.

Sleep-Support carries 0.3 to 1 mg of melatonin, well below many higher-dose commercial melatonin products. That reflects my own formulation preference for a lower-dose approach rather than a high-dose one — a design preference, not a claim that low doses are proven superior to high doses in every clinical context. A fixed low dose is also easier to make consistent than a product where the customer decides how much to take, and consistency of labeled dose is not a small issue in this category: a 2023 laboratory analysis of 25 commercial melatonin gummy products found that 22 of them, or 88 percent, contained melatonin quantities that differed from their label claim by more than the study's threshold, with measured content ranging from 74 to 347 percent of what the label stated.⁸ That study analyzed gummies, not strips, and its findings don't transfer automatically to any other dosage form — a fixed single-strip dose is a design choice that points away from that failure mode, but the actual label accuracy of any MIHIYO strip is a manufacturing and analytical-testing question, not something that follows automatically from being a strip.

Mood-Boost pairs 5-HTP with L-theanine at one fixed daily dose for a related reason: the substantial regimen-dependent differences in 5-HTP exposure observed in a controlled challenge study, together with nausea reported in the carbidopa-enhanced regimen, are part of why I chose to set the dose once, in formulation, rather than leave redosing up to the customer. I've written elsewhere about the honest limits of 5-HTP as a mood-support ingredient — the human trial evidence is real but thin — and the one-strip format doesn't change that; it just keeps the dose the customer is comparing against a known quantity.⁷ Learn more about oral mucosa absorption mechanics or the evidence and limits behind 5-HTP. See the full product line: Energy-Focus, Sleep-Support, and Mood-Boost.

Where one-per-day dosing falls short

This design has real limits, and I'd rather state them than let a customer assume otherwise. First, the compliance research behind this decision comes from studies of prescribed medications generally, not from a study of MIHIYO's own strips — those findings cannot be assumed to transfer quantitatively to supplement use, and I don't have adherence data on our own customers to cite here. Second, one dose a day is the wrong model for any active that genuinely needs steady, round-the-clock coverage; that is not a category MIHIYO's current products are trying to serve, but it is a real category, and a fixed once-daily strip is the wrong tool for it. Third, the film-loading limit described above comes from one loratadine formulation study; it is a real physical constraint on that system, but I have not shown it applies at the same 30 percent threshold to MIHIYO's own films, which use different actives and polymers. Fourth, the melatonin receptor sensitivity data I cited above comes from cloned receptors in cell culture, not from a controlled human dosing trial on repeated same-day strips; I'm citing it as a plausible mechanism, not as proof of what happens in a person. Fifth, dissolving in the mouth is not the same as being absorbed there: some fraction of any strip's content is swallowed rather than absorbed transmucosally, and I have not measured what that split actually is for any MIHIYO product — the mucosal-bypass advantage applies only to the portion that crosses the mucosa, not to the whole labeled dose.

The bottom line

One strip per day dosing is a formulation decision built on three distinct considerations, not one uniform body of evidence: orodispersible films have a real film-loading limit, at least in the one system studied in detail, which constrains what a single strip can carry; oral residence time and salivary clearance bound how much of any single dose is absorbed transmucosally before the rest is swallowed, which constrains what any one dose can do; and once-daily regimens tend to outperform more frequent ones on real-world compliance in medication studies generally, which is the actual evidence for choosing a frequency. The first two are dosage-form and delivery constraints, not proof that once-daily beats twice-daily on their own — and none of it is a claim that MIHIYO's specific strips have been studied this way, or proof that a second same-day strip would fail to add to total systemic exposure. It's the reasoning that shaped the design, not a substitute for testing MIHIYO's own products. The product-design point of view is simple: give the customer one defined dose, once a day, rather than asking them to judge for themselves how many strips to take.

References

1. Centkowska, K., Ławrecka, E., Sznitowska, M. Technology of Orodispersible Polymer Films with Micronized Loratadine — Influence of Different Drug Loadings on Film Properties. Pharmaceutics. 2020;12(3):250. DOI: 10.3390/pharmaceutics12030250
2. Wanasathop, A., Patel, P.B., Choi, H.A., Li, S.K. Permeability of Buccal Mucosa. Pharmaceutics. 2021;13(11):1814. PMID: 34834229. DOI: 10.3390/pharmaceutics13111814
3. Fenoll-Palomares, C., Muñoz Montagud, J.V., Sanchiz, V., et al. Unstimulated salivary flow rate, pH and buffer capacity of saliva in healthy volunteers. Revista Española de Enfermedades Digestivas. 2004;96(11):773-783. PMID: 15584851
4. Claxton, A.J., Cramer, J., Pierce, C. A systematic review of the associations between dose regimens and medication compliance. Clinical Therapeutics. 2001;23(8):1296-1310. PMID: 11558866
5. Willson, C. The clinical toxicology of caffeine: A review and case study. Toxicology Reports. 2018;5:1140-1152. PMID: 30505695. DOI: 10.1016/j.toxrep.2018.11.002
6. Gerdin, M.J., Masana, M.I., Ren, D., Miller, R.J., Dubocovich, M.L. Short-term exposure to melatonin differentially affects the functional sensitivity and trafficking of the hMT1 and hMT2 melatonin receptors. Journal of Pharmacology and Experimental Therapeutics. 2003;304(3):931-939. PMID: 12604667
7. Gijsman, H.J., van Gerven, J.M., de Kam, M.L., et al. Placebo-controlled comparison of three dose-regimens of 5-hydroxytryptophan challenge test in healthy volunteers. Journal of Clinical Psychopharmacology. 2002;22(2):183-189. PMID: 11910264
8. Cohen, P.A., Avula, B., Wang, Y.H., Katragunta, K., Khan, I. Quantity of Melatonin and CBD in Melatonin Gummies Sold in the US. JAMA. 2023;329(16):1401-1402. PMID: 37097362. DOI: 10.1001/jama.2023.2296

By Jack Zheng, MS Pharmacy — Founder of MIHIYO Labs. Focused on the R&D of high-bioavailability, fast-absorption oral dissolving strips.